Background-Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory condition of the sinonasal mucosa consisting of poorly defined subtypes and characterized by variable clinical manifestations, responses to therapy, and underlying pathophysiologies. In the related disorder of asthma, progress has been made in defining disease subtypes on both clinical and pathophysiologic levels, facilitating the development of targeted biologic pharmacotherapy. The potential role of these drugs for the management of CRS will be reviewed.
Introduction
Chronic rhinosinusitis (CRS) is a heterogeneous group of inflammatory disorders that involve the mucosa of the nasal passageways and paranasal sinuses. Currently, a diverse armamentarium exists for the medical management of CRS. The therapeutic mainstays for CRS consist of intranasal corticosteroids, short-term oral corticosteroids, and nasal saline irrigations, which are supported by high-level evidence.(1, 2) Antibiotics in both oral and topical preparations, leukotriene receptor antagonists, and topical nasal decongestants are also commonly included in the medical regimen, but limited evidence is available to support their recommended uses. (2) (3) (4) (5) The estimated success rate of medical therapy in controlling both subjective and objective outcome parameters, however, ranges from 38% to 51%. (3, 6) For CRS patients who are refractory to medical management, surgery serves as a viable therapeutic option, but medical therapy still plays an important adjunctive role following surgery. (7, 8) The widespread use of nonspecific therapies for CRS, as predominantly prescribed in the United States today, generates substantial residual morbidity. For example, the overuse of antibiotic therapy for CRS treatment is likely associated with the development of resistant bacteria.(9) Furthermore, antibiotic use for CRS oftentimes neglects the fact that CRS is primarily an inflammatory disorder, as opposed to an infectious condition. Hence, there is a compelling need for new treatment strategies. Recently, biologic therapies have become increasingly effective and attractive options for asthmatic patients based on their ability to target key asthma inflammatory profiles. (10, 11) Due to similarities in the underlying role of inflammation in asthma and CRS, interest has emerged on the application of biologic therapies to provide potential treatment options for CRS. (12, 13) This article serves as an overview of the current and future developments of biologic therapy for CRS.
Advances in understandings of CRS phenotypes and endotypes
Current research highlights the diverse and multifactorial nature of CRS pathogenesis. (14) (15) (16) Specifically, a dysfunctional interplay between different host susceptibilities and environmental modifiers is speculated to instigate and perpetuate the inflammatory response underlying the clinical syndrome. Environmental factors include infectious pathogens, pollutants, and inhaled allergens, while host contributions involve both congenital and acquired variables, such as anatomical obstruction of the osteomeatal complex, impaired mucociliary clearance, a defective epithelial barrier function, and an aberrant host immune response. (17) Despite the variety of hypotheses proposed to explain CRS, none has singly proven valid for the whole CRS spectrum.
To highlight the different etiologic factors involved with CRS pathogenesis, recent research has emphasized characterizing CRS as a heterogeneous spectrum of disease variants defined by clinically observable features, responses to therapeutic interventions, and presumably distinct, but overlapping, pathophysiologic pathways. (18) (19) (20) The attempt to elucidate the heterogeneity of CRS in terms of clinical manifestations and pathogenesis is rooted in prior studies on asthma, a similar inflammatory disorder that consists of multiple disease variants. (10, 21) Today, asthma phenotypes refer to common variants recognized by clinically observable properties, including severity of disease, age of disease onset, and association with atopy. Disease endotypes, on the other hand, are defined by the specific biological pathways driving the observable phenotypic characteristics. Identification of asthma endotypes according to the distinct pathophysiologic mechanisms of inflammation has increasingly given a role for biologic pharmacotherapy through the targeting of biomolecules specific to the endotypic variants. Most importantly, certain asthmatic endotypes have correlated with response to certain medications such as inhaled corticosteroid. (22) The comorbid association between CRS and asthma is clearly established in epidemiologic studies, highlighting similar immunologic patterns of inflammation occurring at the epithelial cell layers of the upper and lower airways. (23) (24) (25) The subset of patients with the most severe forms of CRS and consequently those most likely to lack success with the traditional treatment regimens are commonly patients with comorbid asthma. (1, 26) Given the parallels in pathophysiology between asthma and CRS, various immunobiologic factors that are suspected to drive the inflammatory processes of asthma, such as immunoglobulin (Ig) E and interleukin (IL)-5, have by translation become likely targets for biologic therapy in CRS. Despite the potential utility of these therapies in CRS, the successful application of such agents requires the proper identification of patients who demonstrate the appropriate endotypic profiles.
As in asthma, phenotypes in CRS are based upon clinically observable characteristics, while CRS endotyping is based on different molecular pathways important in disease pathogenesis. For CRS, the absence or presence of nasal polyposis on endoscopic examination serves as the most frequent method of distinguishing two basic phenotypes: CRS with nasal polyposis (CRSwNP) and CRS without nasal polyposis (CRSsNP). (1, 27, 28) Over recent years, this distinction has proven to be overly broad and simplistic, as multiple studies have found significant clinical variations in disease course, responsiveness to therapeutic interventions, and risk of recidivism even within the CRSwNP and CRSsNP subgroups. (29, 30) Increasing emphasis has therefore been placed on the endotypic stratification of CRSwNP and CRSsNP subgroups according to the distinctive pathophysiologic mechanisms, which most likely account for the variations in clinical manifestations and outcomes. Definitions for CRS phenotypes and endotypes, however, remain less developed than those for asthma, which by comparison are based on stronger and more extensive data.
One current attempt to endotype CRS has focused on the inflammatory milieu composed of different cytokine profiles, which are elevated in both CRSwNP and CRSsNP. The most common scheme to subclassify CRSwNP and CRSsNP has been based upon the balance of type 1 and type 2 inflammatory patterns. Type 1 inflammation is characterized by the presence of neutrophils; elevated type 1 cytokines, such as interferon (IFN)-γ; and T-helper 1 (Th1) cells. On the other hand, type 2 inflammation is characterized by the high presence of eosinophils, mast cells, and basophils; elevated type 2 cytokines, including IL-4, IL-5, and IL-13; and T-helper 2 (Th2) cells. CRSwNP has been associated with skewed type 2 inflammation, in which IL-4 plays an important unifying role in supporting the induction of IgE-mediated immune responses and the upregulation of basophils, mast cells, and eosinophils. CRSsNP, in contrast, has been characterized by a relative skewing away from type 2 inflammation and toward more type 1 inflammation, with Th1 and T-helper 17 (Th17) cytokine patterns. (29, 31) CRSsNP is also more closely associated with neutrophilic tissue infiltration, although eosinophils are also commonly present in CRSsNP, albeit at significantly lower levels than in CRSwNP. (1) The general use of inflammatory profiles to characterize patterns of immunologic expression in patients with CRSwNP and CRSsNP, however, is not absolute and requires continued investigation. (1, (30) (31) (32) (33) (34) Present research on the endotypic variants of CRS highlight the potential applications of certain biologic therapy that target specific biomarkers driving the inflammatory response of CRS. Multiple agents targeting type 2 cytokine inflammatory byproducts have been developed and more thoroughly studied for disease control in eosinophilic and allergic asthma and are thus potential therapeutic candidates for use in CRS. (21, 35) For CRS, significant attention regarding biologic therapies is also generally directed to CRSwNP in Caucasian populations, in whom the inflammatory response is induced by Th2 cells, eosinophils, and associated type 2 pro-inflammatory cytokines. However, the clinical efficacy and utility of these agents in CRS remain in the early and experimental phases of study. Table 1 highlights the currently available randomized controlled studies of biologic therapies specifically for CRS.
Targeting the IgE pathway
The most promising biologic therapy for CRS to date has been omalizumab, which is an approved treatment option in the United States and Europe for patients with severe allergic asthma. Omalizumab has also demonstrated positive results for CRSwNP patients in a recent randomized, double-blind, placebo-controlled study. (36) The mechanism of action of omalizumab, a recombinant humanized monoclonal antibody, involves its selective binding to free circulating IgE, which decreases the expression of IgE receptors on mast cells, basophils, and dendritic cells and thereby interferes with activation of these effector cells. In the study by Gevaert et al, the subcutaneous administration of four to eight doses of omalizumab was found to result in significant reduction of polyp size on endoscopic examination, Lund-MacKay scores on radiologic imaging, and a variety of disease-specific quality-of-life questionnaire scores when compared to placebo. Interestingly, the improvements in upper and lower airway diseases following use of anti-IgE therapy were seen independent of serum IgE levels. These findings support the involvement of local mucosal IgE production in the upper airways in the pathogenesis of nasal polyps and suggest that omalizumab may offer therapeutic improvements for both allergic and nonallergic variants of CRSwNP. Due to the small study population in the existing study, however, further studies with larger population sizes are needed.
The results from the study by Gevaert et al are nonetheless encouraging, given that an earlier randomized, double-blinded, placebo-controlled trial with omalizumab had previously demonstrated a lack of significant difference between anti-IgE therapy and placebo in patients with severe CRS refractory to standard treatments, including sinus surgery. (37) In the earlier trial by Pinto et al, the treatment group was given subcutaneous doses of omalizumab at 4-week intervals over a course of 6 months. Outcome measurements included Lund-MacKay scores from sinus imaging and various qualitative gauges on symptomatic and quality-of-life improvements. The study, however, was underpowered due to recruitment problems after warnings were raised about anaphylactic events following administration of omalizumab. Moreover, this study did not provide details about distinguishing between CRSwNP and CRSsNP in the recruitment of study subjects for both treatment and control groups.
While the available data may suggest that more widespread application of omalizumab for CRSwNP is an increasingly viable option, regardless of asthma status or systemic atopy, the cost and toxicity of omalizumab remain prohibitive factors to the biologic agent's broad application for CRSwNP. Chronic maintenance therapy may or may not be necessary to control polyp growth. Although the side effects of anti-IgE therapy in the two prior randomized, double-blinded, placebo-controlled trials have generally been negligible, issues have been raised in regard to three main areas: malignancy, cardiovascular disease, and anaphylaxis. The incidence of anaphylaxis is approximately 0.2%, thus mandating administration in a health care setting. (38) Recent data evaluating the longer-term risk of malignancy, however, have indicated no difference in the rate of malignancy in omalizumabtreated versus placebo-treated patients. (39) The rationale for the use of omalizumab in severe asthma, which has an uncommon but not insignificant mortality, is more easily supported when compared to use in CRS.
Targeting the IL-5 pathway
As a target for biologic therapy in asthma, IL-5 is a type 2 cytokine that serves as an essential role in the terminal differentiation of bone marrow eosinophilic progenitors to develop into mature eosinophils. (40, 41) The prevalence of IL-5 as an inflammatory mediator in CRSwNP has allowed for the targeting of IL-5 in CRS pharmacotherapy with the use of reslizumab and mepolizumab, both anti-IL-5 monoclonal antibodies. Efficacy of reslizumab was first suggested in a randomized, double-blind, placebo-controlled trial, in which CRSwNP patients were treated with single doses of reslizumab or placebo.(42) At 12 weeks following administration of reslizumab, the majority of study participants who received the agent at the 1 mg/kg dosage demonstrated smaller polyp sizes, improved patient-reported symptom scores, and reduced blood eosinophil levels when compared with their baseline values. The study patients who responded to reslizumab were found to have elevated nasal IL-5 levels at baseline, compared to the nonresponders. Interestingly, blood eosinophil counts initially dropped significantly in patients who received reslizumab, but after discontinuation of reslizumab, showed an increase above baseline values, suggesting a rebound effect with resultant hypereosinophilia.
A more recent phase II study with anti-IL-5 antibodies for CRSwNP by the same group of investigators further indicated the potential utility of IL-5 inhibition as a therapeutic approach in patients with severe eosinophilic CRSwNP. (43) In this randomized, placebocontrolled trial, CRSwNP patients were randomized to receive either two injections of mepolizumab given 28 days apart, or placebo. While the nasal polyp score improved in the treatment group 8 weeks following the first injection, it remained unchanged in the placebo group. In addition, significantly less opacification on CT imaging was observed in the treatment group. The subgroup of patients who responded to anti-IL-5 therapy with polyp shrinkage also demonstrated a decrease in some indicators of type 2 inflammation in nasal secretions. Although the group's initial pilot trial with reslizumab suggested that nasal IL-5 levels could predict responders, this follow-up study showed that the effects of mepolizumab was independent of nasal IL-5 levels. Therefore, despite the encouraging results, no clinical or laboratory parameter, other than perhaps nasal polyp eosinophilia has been identified as a predictor of therapeutic response, has been identified as a predictor of therapeutic response that can enhance the success rate.
Benralizumab has been another recent biologic agent that imparts its inhibitory effect on the IL-5 pathway and the resulting inflammatory cascade related to the development of asthma and possibly CRS. Instead of directly neutralizing free IL-5 levels in serum, benralizumab serves as a humanized afucosylated monoclonal antibody that targets the IL-5 receptor (IL-5R) located on eosinophils, basophils, and their corresponding progenitors. The subsequent binding of benralizumab to IL-5R on effector cells is suspected to result in a competitive inhibition of IL-5 and also induction of apoptosis of eosinophils and basophils. (44-46) Laviolette et al recently conducted a randomized, placebo-controlled phase I trial with benralizumab in patients with eosinophilic asthma.(44) This clinical study found that patients who received either a single intravenous dose of benralizumab or three monthly subcutaneous doses of benralizumab demonstrated reduced eosinophil counts in the airway mucosa, sputum, bone marrow, and peripheral blood, when compared to the control groups receiving a placebo. Additionally, blood basophil levels were also lowered following administration of benralizumab. Compared to reslizumab and mepolizumab, benralizumab provides the unique targeting of not only eosinophils, but also basophils, which have been found in elevated levels in CRSwNP patients. (47) Continued studies on the effects of benralizumab on outcome measurements in asthma and especially CRSwNP patients are necessary.
Targeting the IL-4/IL-13 pathway
The IL-4/IL-13 signaling pathway serves as a prime example of how the immunohistopathologic similarities of the respiratory epithelium in the lower and upper airways support the potential application of biologic targets in asthma pharmacotherapy for CRS management. In both asthma and CRS, IL-4 and IL-13 are important cytokines that drive Th2 cell differentiation, activate type 2 inflammatory responses via IgE synthesis and eosinophil, mast cell, and basophil recruitment, and also modulate airway remodeling through mucus hypersecretion and matrix deposition. (48, 49) In the asthma literature, clinical studies have previously assessed the IL-4/IL-13 signaling pathway and its effects on varying outcome parameters, such as measures of pulmonary function, levels of downstream inflammatory mediators, and symptom-based scores. Past examples of these biologic therapies for asthma have included pascolizumab, a monoclonal antibody targeting free IL-4; anrukinzumab and lebrikizumab, monoclonal antibodies targeting free soluble IL-13; and altrakincept, a soluble recombinant human IL-4 receptor (IL-4R), which specifically binds and competitively inhibits free IL-4.(50-53) Unfortunately, these clinical studies displayed equivocal results with varying therapeutic benefits for asthmatic patients.
More recent research on biologic therapies for asthma has focused on the simultaneous targeting of both IL-4 and IL-13, as opposed to targeting of either cytokine individually, in order to cause a more comprehensive inhibition of the type 2 inflammatory pathway. Given that the alpha subunit of IL-4R (IL-4Rα) is common to both the IL-4 and IL-13 receptors and that monoclonal antibodies that target IL-4Rα thereby block the actions of both cytokines, several clinical trials have shown a potential role for targeting IL-4Rα to improve clinical endpoints in patients with asthma and atopic dermatitis. (54) (55) (56) In particular, dupilumab, a humanized monoclonal antibody directed against IL-4Rα, has recently demonstrated overall therapeutic efficacy in a randomized, double-blinded, placebocontrolled trial for patients with CRSwNP refractory to intranasal corticosteroids. (57) In the clinical trial by Bachert et al, the addition of subcutaneous dupilumab to mometasone furoate nasal sprays for a 16-week period was found to reduce nasal polyp burden, decrease Lund-Mackay scores, and improve both olfactory and disease-specific quality-of-life questionnaire scores, when compared to use of mometasone sprays alone. These encouraging results suggest that biologic therapy specifically targeting IL-4Rα may become a viable treatment option for a variety of inflammatory conditions, including well-defined CRS endotypes.
Targeting the epithelial cell-derived cytokine pathway
Increasing research on the regulation of the type 2 inflammatory response in CRSwNP has additionally focused on the role of the mucosal epithelium, which not only provides a mechanical barrier to the external environment, but also actively stimulates the host innate and acquired immune responses through cytokine production. These epithelial cell-derived cytokines, including thymic stromal lymphopoietin (TSLP), IL-33, and IL-25, have shown the capacity to activate type 2 innate lymphoid cells (ILC2s), a subset of innate immune cells which release significant amounts of type 2 cytokines, including IL-5 and IL-13, in the absence of specific immune activation.(58-61) TSLP, IL-33, and IL-25 also influence acquired immune responses by fostering Th2 lymphocyte differentiation with an amplified type 2 cytokine response. (62, 63) Overall, epithelial cell-derived cytokines promote important upstream mechanisms that drive the type 2 inflammation observed in CRSwNP. Targeting these key biomolecules involved in these immunologic pathways may ultimately offer more effective pharmacologic methods to alter the inflammatory responses in CRSwNP.
For one, TSLP is a cytokine derived from epithelial cells of various organ systems that is linked to such inflammatory disorders as atopic dermatitis, eosinophilic esophagitis, and asthma. TSLP upregulates the expression of OX40 ligand on dendritic cells, which by interacting with the OX40 receptor on CD4 T cells, mediates the differentiation of naïve T-cells into Th2 cells. TSLP also augments the function and activity of ILC2s, which highly express the TSLP surface receptor. (58, 64) Furthermore, TSLP synergizes the inflammatory effects of IL-1 in activating the production of Th2 cytokines by mast cells. In a double-blind, placebo-controlled study, AMG 157, a human monoclonal antibody that binds human TSLP and prevents its receptor interaction, showed efficacy in decreasing allergen-induced bronchoconstriction and eosinophil levels in the sputum and blood of asthmatic patients. (65 (75) Furthermore, in this same study, an IL-25 neutralizing antibody was tested in the murine model, resulting in a lower number of nasal polypoid lesions; a reduced thickness in the polyp mucosa; and a suppressed expression of IL-25 and associated cytokines. These study findings suggest a potential use of anti-IL-25 therapy as a novel treatment strategy for CRSwNP, although this directed approach requires further investigation into its efficacy and safety in human patients with CRSwNP. 
Conclusion
In CRS, the varying immunologic and histologic profiles reflect the pathophysiologic mechanisms by which inflammation is initiated and propagated. Improved understandings of these pathophysiologic pathways have expanded the recognition of CRS subsets, thereby enhancing the diagnostic criteria for CRS endotypes and raising the possibility of using pharmacotherapy to target the pathways present in individual patients.
Recent developments and clinical studies on various biologic therapies, including those targeting the IgE, IL-5, IL-4/IL-13, and epithelial cell-derived cytokine pathways, further open the door to more innovative strategies for the management of CRS in general and CRSwNP in particular. Biologic therapy for CRS thus provides a shift in the paradigm of medical treatments, which traditionally has relied on nonspecific therapies but has progressively focused more on target-specific treatments that may be efficacious in patients with certain CRS phenotypic and endotypic characteristics. 
